Navigation Links
AMRESCO Invests in New Powder Manufacturing Facility to Support Growth in Life Science Business
Date:6/25/2013

Cleveland, Ohio (PRWEB) June 25, 2013

AMRESCO, LLC, a VWR company and a Life Science leader in the supply and contract manufacturing of high purity biochemicals, reagents and research products, announced that it has invested in a new powder manufacturing facility to support growing global business to Diagnostic, Molecular Biology and Biopharmaceutical companies. AMRESCO’s investment is part of its ongoing strategy to help increase its customers’ operational efficiencies and profitability. Its breadth of services and manufacturing capabilities offers a strong value platform and strengthens its mission to support customers and their products.

AMRESCO’s new facility increases its powder manufacturing capacity by 150%, expanding capabilities for particle size reduction, homogenous powder blending, precision powder dosing for pouching, and tablet production. This expanded and enhanced production helps to support growing product lines such as buffer blends and dehydrated media blends.

Over 35% of AMRESCO’s customers require specific formulation needs. The additional powder manufacturing capabilities and capacity allow AMRESCO to manufacture, dose and package a wider variety of powder products with varying volumes, as well as offer customers the sensitivity and most importantly, the throughput that their product requires.

Jim Taliak, VP of Global Sales at AMRESCO states, “Our customers are challenged with speed to market, operational constraints, and lack of capital or expertise. They are focusing on activities and efforts that don’t always align with their best strategic interest. Together, we look at where they need to be, then employ our skill and capabilities to assure their success.”

ABOUT AMRESCO
For nearly four decades, AMRESCO has been serving life sciences research and commercial production customers worldwide, bringing them high purity biochemicals, custom manufacturing solutions, innovative research products and strategic services including Product Design, Transfer and Engineering. AMRESCO products and services support the growing In Vitro Diagnostic, Molecular Diagnostic, Life Science Tool Providers and Biopharm market segments.

For further information, contact: Deborah Neilly, Marketing and Communications
V: 440.914.3311 E: dneilly(at)amresco-inc(dot)com

Read the full story at http://www.prweb.com/releases/2013/6/prweb10854471.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. AMRESCO’s New Fluorescent DNA Quantitation Kit Uses a Highly Specific DNA-binding Dye that Allows Accurate Quantitation Even in Crude Extracts
2. AMRESCO’s New VisiGlo™ Prime and VisiGlo™ Select HRP Chemiluminescent Substrate Kits Offer Long-lasting, High Sensitivity Detection
3. AMRESCO Offers New Prism Protein Marker With Vibrant Colors For Easy Band Identification
4. DuPont, American Farm Bureau Foundation Invests $250,000 in My American Farm Web Education Program
5. UPMC Invests in Intelligent Infrastructure with IBM to Support Vision of Personalized Medicine
6. JumpStart Invests $250,000 in Milo Biotechnology
7. AFFiRiS AG Invests Into Human Capital - Chief Business Officer Recruited
8. SAFC Expands Irvine Facility to Add Dry Powder Media Manufacturing Capabilities
9. TM&S Opens Office Dedicated to Powder Metal, Metal Injection Molding and Liquid Metal
10. Rigaku Publishes New Application for Cement Analysis by the Pressed Powder Method on the ZSX Primus III+ According to ASTM C114-11
11. Rigaku Publishes New Application Note: Cement Raw Meal Analysis by Pressed Powder Method on the ZSX Primus III+
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , March 29, 2017  Halozyme Therapeutics, Inc. ... and drug-delivery therapies, today announced that an Oncologic ... Drug Administration voted 11 to 0 that the ... injection was favorable for patients in the proposed ... and chronic lymphocytic leukemia. The FDA action date ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... it is exhibiting in booth 513 at the Association of Community Cancer Centers ... Hotel, March 29-31. , CANCERSCAPE unites key stakeholders from leading national organizations ...
(Date:3/29/2017)... and NEWARK, Del. , March ... privately-held regenerative medicine company, and W. L. Gore ... company, today announced a collaborative research agreement whereby the ... cell therapy delivery device technologies that provide protection from ... decade, ViaCyte has been developing innovative stem cell-derived cell ...
(Date:3/29/2017)... 29, 2017 Research and Markets has ... and Global Markets" report to their offering. ... The study ... sequencing, biochips, RNA interference, synthetic biology tools and genome editing ... These technologies and products are analyzed to determine ...
Breaking Biology Technology:
(Date:3/6/2017)... , March 6, 2017 ... sales technology, today announced Predictive Sales Coach TM ... infusing actionable sales intelligence into Salesforce. This unique ... enable their sales organizations with deep knowledge of ... allow for intelligent engagement. Predictive Sales Coach extends ...
(Date:3/2/2017)... 2017 Summary This report provides ... KGaA and its partnering interests and activities since 2010. ... Description The Partnering Deals and Alliance since 2010 report ... one of the world,s leading life sciences companies. ... to ensure inclusion of the most up to date ...
(Date:3/2/2017)... , March 2, 2017 Australian stem cell ... (ASX: CYP), has signed an agreement with the Monash ... Monash Biomedicine Discovery Institute and Department of Pharmacology at ... a further preclinical study to support the use of ... asthma.  Asthma is a chronic, long ...
Breaking Biology News(10 mins):